Join our mailing list
Get exclusive deals and learn about new products!
Reliable shipping
Flexible returns
This volume, a state-of-the-art review of early phase clinical trials for cancer immunotherapy, discusses biomarker selection, combinatorial strategies and their safety or toxicity, determination of Phase 2 dosing, endpoints in the setting of radiographic pseudoprogression, histology selection, and novel immunotherapeutics as they relate to early phase cancer immunotherapy.
Published by: Springer
Publication Date: 2017-11-10
Format: Hardcover
ISBN-13: 9783319637563
DOI: 10.1007/978-3-319-63757-0
Dimensions: 235cm x155cm
Pages: 331